Target, across the briefings
PDCD1 across 6 cancers
PDCD1 is on the target list of 6 of the briefings. A drug aimed at it carries an FDA label naming the disease in 6, and is approved for some indication in 6.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials |
|---|---|---|---|---|
| Esophageal cancer | approved here Nivolumab, Pembrolizumab, Tislelizumab | approved | 26 | 6 via PD-1 |
| Hodgkin lymphoma | approved here Nivolumab, Pembrolizumab | approved | 26 | 35 via PD-1 |
| Melanoma | approved here Nivolumab, Pembrolizumab | approved | 26 | 16 via PD-1 |
| Head and neck cancer | approved here Nivolumab, Pembrolizumab | approved | 26 | 10 via PD-1 |
| Cervical cancer | approved here Pembrolizumab | approved | 26 | 10 via PD-1 |
| Anal cancer | approved here Retifanlimab | approved | 26 | 2 via PD-1 |
"Approved here" means a drug Open Targets records as aimed at PDCD1 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov.